PharmaFocus: Tauopathies–Global Market Analysis

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no treatments approved in this therapy area and five tauopathies are attracting increasing attention from pharmaceutical companies in particular. These are: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Pick’s disease (clinically referred to as bvFTD), and chronic traumatic encephalopathy (CTE). In these indications, symptoms often present as behavioral (e.g. disinhibition, apathy), cognitive (e.g. memory loss), language (e.g. slurring of speech), or motor (e.g. falls, tremor) deficits. A multitude of treatments are used off-label to alleviate patients’ symptoms and they include those indicated for Parkinson’s disease, Alzheimer’s disease, or depression. Growth in tauopathies market is likely to be driven by the introduction of novel treatments into the market while continued lack of quantitative biomarkers will be a major barrier to the growth of the tauopathies market.

Scope

Overview of tauopathies including, etiology, pathophysiology, symptoms, diagnosis, and clinical trial challenges.

Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the tauopathy therapeutics market.

Pipeline analysis: focus on four late-stage pipeline tauopathy drugs, discussing emerging trends as well as an overview of earlier phase and preclinical drugs.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

Develop business strategies by understanding the trends shaping and driving the global tauopathy therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global tauopathy therapeutics market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Key Questions Answered

The tauopathies market is in its infancy with limited choices of symptomatic treatments being offered off-label. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers in the near future?

There are five substantial unmet needs that exist in the tauopathies market. Will pipeline drugs fulfil any of the unmet needs for tauopathies? Which unmet needs will provide opportunity for drug developers?

Four products are currently in late-stage of development. What unmet needs will these drugs fulfil? How will they affect the treatment algorithm for tauopathy patients?

Many challenges exist for companies entering the tauopathies market. What are the key challenges involved in clinical trials? What strategies are companies using to enter the tauopathies market?"

AbbVie
AB Science
Alectos Therapeutics
AlzProtect
Anavex Life Sciences
Asceneuron
Avanir Pharmaceuticals
Biogen
Brighton Biotech
Bristol-Myers Squibb
Catalent
Cortice Biosciences
C2N Diagnostics
Déclion Pharmaceuticals
Delta Crystallon
Eli Lilly
Gismo Therapeutics
GSK
Intellect Neurosciences
Kannalife Sciences
Merck & Co.
Neurimmune Holding
Otsuka
Pfizer
Prana Biotechnology
PresSura Neuro
Sellas Lifesciences Group
TauRx Pharmaceuticals

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification

3.2.1 Clinical Classification

3.2.2 Pathological Classification

3.2.3 Classification According to 4R:3R Ratio

3.3 Symptoms

3.4 Diagnosis

3.4.1 Patient Journey

3.4.2 Clinical Assessments

3.5 Biomarkers

3.5.1 Diagnostic Markers

3.5.2 Biomarkers in Drug Development

3.5.3 Promising Biomarkers

3.6 Prognosis

3.7 Quality of Life

4 Current Treatment Paradigm

4.1 Overview

4.2 Treatment Paradigm

4.3 Anti-Parkinson’s Drugs

4.3.1 Amantadine

4.3.2 Dopamine Receptor Agonists

4.3.3 Levodopa

4.4 Antidepressant Drugs

4.4.1 Selective Serotonin Reuptake Inhibitors

4.4.2 Trazodone

4.4.3 Tricyclic Antidepressants

4.5 Anti-Alzheimer’s Drugs

4.5.1 Acetylcholinesterase Inhibitors

4.5.2 Memantine

4.6 Other Therapeutic Agents

4.6.1 Antiepileptics

4.6.2 Antipsychotics

4.6.3 Onabotulinum Toxin A

4.7 Non-pharmacological Therapies

5 Unmet Needs and Opportunities

5.1 Overview

5.2 Development of Disease-Modifying Therapies

5.2.1 Unmet Need

5.2.2 Gap Analysis

5.2.3 Opportunity

5.3 Development of More Effective Symptomatic Treatments

5.3.1 Unmet Need

5.3.2 Gap Analysis

5.3.3 Opportunity

5.4 Improved Biomarkers to Evaluate Drug Efficacy

5.4.1 Unmet Need

5.4.2 Gap Analysis

5.4.3 Opportunity

5.5 Biomarkers for Clinical Diagnosis

5.5.1 Unmet Need

5.5.2 Gap Analysis

5.5.3 Opportunity

5.6 Greater Support for Patients

5.6.1 Unmet Need

5.6.2 Gap Analysis

5.6.3 Opportunity

6 Pipeline Assessment

6.1 Overview

6.2 Clinical Trial Mapping

6.2.1 Clinical Trials by Class of Therapy

6.3 Drugs in Late-Stage Clinical Development

6.3.1 AVP-786

6.3.2 Masitinib

6.3.3 TRx-237

6.3.4 Zolpidem Tartrate

6.4 Drugs in Early-Stage Clinical Development

6.4.1 ABBV-8E12

6.4.2 AZP-2006

6.4.3 BMS-986168

6.4.4 DC-TAB

6.4.5 MK-8719

6.4.6 TPI-287

6.5 Drugs in Preclinical/Discovery Development

6.5.1 ASN-561

6.5.2 ANAVEX-3-71

6.5.3 Cannabidiol

6.5.4 DP-C016

6.5.5 EU-C-001

6.5.6 GTC-6000

6.5.7 N-acetylcysteine Amide

6.5.8 NI-205/NI-308

6.5.9 PBT-434

6.5.10 Anti-TauC3

7 R&D Strategies and Clinical Trial Design

7.1 Overview

7.1.1 Trends in Corporate Strategies

7.1.2 Novel Research Strategies

7.1.3 Clinical Trial Design

8 Market Drivers and Barriers

8.1 Overview

8.2 Driver: First-to-Market Drug Will Boost Sales and Encourage Pharma Companies to Focus R&D Efforts in This Market

8.3 Driver: Approval of Drug in One Tauopathy Indication is Likely to Prompt its Off-Label Use in Others

8.4 Driver: Any Tauopathy-Approved Drug Is Likely to Enter the Lucrative Alzheimer’s DiseaseMarket

8.5 Driver: Regulatory Agencies Provide Orphan Designations to Drug Candidates

8.6 Driver: Therapies Are Likely to Have Premium Pricing

8.7 Barrier: No Biomarker to Measure Clinical Efficacy

8.8 Barrier: Low Accuracy in Diagnostic Methods

8.9 Barrier: Tauopathies Market Is a High-Risk Indication

8.10 Barrier: Low Public Awareness of These Disorders

9 Appendix

9.1 Bibliography

9.2 Abbreviations

9.3 Methodology

9.4 Primary Research – KOLs Interviewed for This Report

9.5 About the Authors

9.5.1 Analyst

9.5.2 Therapy Area Director

9.5.3 Global Director of Therapy Analysis and Epidemiology

9.6 About GlobalData

9.7 Disclaimer

Table

Table 1: Main Distinctions of the FiveTauopathies

Table 2: Genetic Traits in Tauopathies

Table 3: Isoform Expressions in Tauopathies

Table 4: Cellular Tau Pathology in Different Tauopathies

Table 5: Characteristic Symptoms of Tauopathies

Table 6: Classification and Criteria of FTD According to DSM-V and ICD-10-CM

Table 7: Diagnostic Markers for Tauopathies

Table 8: Treatments for Tauopathies, 2016

Table 9: Unmet Need and Opportunity in Tauopathies

Table 10: Drugs in Clinical Development for Tauopathies, 2016

Table 11: Comparison of Drugs in Development for Tauopathies, 2016

Table 12: Product Profile – AVP-786

Table 13: AEs at ≥3% Incidence in PBA Trials of Nuedexta

Table 14: SWOT Analysis – AVP-786, 2016

Table 15: Product Profile – Masitinib

Table 16: SWOT Analysis – Masitinib, 2016

Table 17: Product Profile – TRx-237

Table 18: SWOT Analysis – TRx-237, 2016

Table 19: Product Profile – Zolpidem

Table 20: AEs at ≥1% Incidence in Insomnia Trials of Zolpidem Lasting up to 10 Nights

Table 21: AEs at ≥1% Incidence in Insomnia Trials of Zolpidem Lasting up to 35 Nights

Table 22: SWOT Analysis – Zolpidem, 2016

Table 23: Drugs in Early-Stage Clinical Development for Tauopathies, 2016

Table 24: Drugs in Preclinical Development for Tauopathies, 2016

Table 25: Comparison of Novel Research Strategies for Tauopathies, 2016

Table 26: Clinical Trial Design of Key Pipeline Drugs for Tauopathies, 2016

Table 27: Recently failed major trials in tauopathies

Table 28: Common Primary and Secondary Outcome Measures in Tauopathies Clinical Trials

Table 29: Tauopathies – Market Drivers and Barriers

Figures

Figure 1: Key Atrophic Brain Regions Involved in Tauopathies

Figure 2: Location of MAPT Gene Within Chromosome 17

Figure 3: Tau 3R and 4R Isoforms Coded by the MAPT Gene

Figure 4: Mechanisms Involved in Tau Dissociation from the MTs

Figure 5: Classification of Tauopathies According to Symptoms

Figure 6: Classification of Primary and Secondary Tauopathies

Figure 7: Tauopathies Therapeutics – Clinical Trials in the 7MM, 2016

Figure 8: Tauopathies Phase II/Phase III Pipeline, 2016

Figure 9: Novel Strategies for Tauopathy Treatment, 2016

Frequently asked questions

PharmaFocus: Tauopathies–Global Market Analysis thematic reports
Currency USD
$9,495

Can be used by individual purchaser only

$28,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

PharmaFocus: Tauopathies–Global Market Analysis was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PharmaFocus: Tauopathies–Global Market Analysis in real time.

  • Access a live PharmaFocus: Tauopathies–Global Market Analysis dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.